Hims & Hers Dips Into Men’s Cardiovascular Health
Hims & Hers can now provide treatment to men for cardiovascular issues, the company recently announced. This treatment combines sexual health and heart health together in a single pill.
Hims & Hers can now provide treatment to men for cardiovascular issues, the company recently announced. This treatment combines sexual health and heart health together in a single pill.
Eko recently launched an AI-powered software that its CEO describes as "Shazam for heartbeats." The platform connects with Eko's digital stethoscopes and identifies whether or not a patient's heart sounds are indicative of disease.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Medical imaging company Genetesis recently closed a $17.5 million Series C funding round, bringing its total funding to date to more than $40 million. Most of the funds will go toward clinical trials for the company's 5-minute test to detect ischemic heart disease, which uses magnetocardiography. Genetesis anticipates the test entering the market in early 2023.
An Ionis Pharmaceuticals heart disease drug beat a placebo in a mid-stage clinical trial, but partner AstraZeneca has decided it won’t advance the genetic medicine to a larger Phase 3 test. The results were apparently not enough to set the Ionis therapy apart from commercialized cholesterol-lowering drugs that address the same protein target.
Pfizer is stopping work on a drug for a rare heart disease after an interim look at Phase 3 data indicated that the study was unlikely to succeed. The small molecule came to Pfizer’s drug pipeline as part of the $11.4 billion acquisition of Array Biopharma in 2019.
A better coronary artery stent cannot help a patient who cannot afford it, does not know they need it, doesn’t have a doctor who can make a diagnosis and identify that need. To help these patients, we urgently need to look at health equity.
Oben Health, a San Francisco-based company developing a digital treatment platform to fight heart disease without medication or surgery, recently received funding from AWS' accelerator for early-stage startups led by founders from underrepresented groups. The startup will use the money to scale its platform and help conduct a pilot program to better understand its model's clinical validity.
The Eko App uses automated disease detection software and is paired with the company's line of smart stethoscopes to analyze heart sounds with FDA-cleared AI algorithms. The redesigned app includes a range of new features to analyze heart sounds and cardiac rhythm for potential problems, the company said.
The ViVE conference last week was a refreshing collection of discussions exploring how much progress has been made in healthcare transformation and the enormous amount of work yet to be done.
Dr. Eric Topol, director of Scripps Translational Science Institute, said: "The mSToPS trial has the potential to upgrade and refine our approach in screening for heart arrhythmias, and at the same time demonstrate the value of large, real-world clinical trials using digital medicine technologies.”
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Examining the retina is not just useful for vision care. With high-powered camera capabilities, evidence of a blocked artery in the heart are even visible.
Bay Area startup MyoKardia just filed for an IPO with the SEC for its precision medicine approach to genetic heart disease. Specifically, it's developing small molecule drugs to treat cardiomyopathies.
Among the observations: it's not good enough to look at apps as a standalone intervention strategy.
Susan Hertzberg, Boston Heart Diagnostics CEO said although genomic sequencing holds a lot of promise beyond cancer treatment, "right here, right now, we have not optimized or used fully what's available."
When it comes to childhood obesity, who is to blame?